potassium calcium-activated channel subfamily M alpha 1
RGD ID:
620715
Description:
Exhibits identical protein binding activity; large conductance calcium-activated potassium channel activity; and ligand-gated ion channel activity involved in regulation of presynaptic membrane potential. Involved in several processes, including negative regulation of small intestine smooth muscle contraction; positive regulation of neuron apoptotic process; and response to estrogen. Localizes to several cellular components, including external side of plasma membrane; glutamatergic synapse; and integral component of presynaptic active zone membrane. Colocalizes with mitochondrion. Human ortholog(s) of this gene implicated in Alzheimer's disease and idiopathic generalized epilepsy. Orthologous to human KCNMA1 (potassium calcium-activated channel subfamily M alpha 1); INTERACTS WITH (+)-pilocarpine; (+)-Pimaric acid; (R)-noradrenaline.
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA, [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA, [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of KCNMA1 mRNA
[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium, Lithocholic Acid promotes the reaction [[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium]
[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium, Lithocholic Acid promotes the reaction [[KCNMB1 protein co-treated with KCNMA1 protein] results in increased transport of Calcium]
Dexamethasone inhibits the reaction [nitrofen results in decreased expression of KCNMA1 mRNA], Dexamethasone inhibits the reaction [nitrofen results in decreased expression of KCNMA1 protein]
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of KCNMA1 mRNA
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA, [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein
Oxygen deficiency results in increased expression of KCNMA1 mRNA alternative form, Oxygen deficiency results in increased expression of KCNMA1 protein alternative form
[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 mRNA, [Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein co-treated with Indomethacin co-treated with rosiglitazone co-treated with Triiodothyronine] results in increased expression of KCNMA1 protein
[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of KCNMA1 mRNA
Lithocholic Acid analog results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein], Lithocholic Acid results in increased activity of [KCNMB1 protein co-treated with KCNMA1 protein]
KCNMA1 mRNA alternative form results in increased susceptibility to Lithocholic Acid, KCNMA1 protein results in increased susceptibility to Lithocholic Acid
Dexamethasone inhibits the reaction [nitrofen results in decreased expression of KCNMA1 mRNA], Dexamethasone inhibits the reaction [nitrofen results in decreased expression of KCNMA1 protein]
[Estradiol co-treated with Progesterone] results in increased expression of KCNMA1 mRNA, Progesterone inhibits the reaction [Estradiol results in increased activity of KCNMA1 protein]
Tamoxifen inhibits the reaction [Glucose inhibits the reaction [[KCNMA1 protein binds to KCNMB1 protein] which results in decreased expression of BCL2 protein]], Tamoxifen inhibits the reaction [Glucose results in decreased activity of [KCNMA1 protein binds to KCNMB1 protein]]
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin